Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 33

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 33
---
” ON PROPOSAL 4. 21

TABLE OF CONTENTS

EXECUTIVE OFFICERS Each of our executive officers serves at the discretion of the Board. The determination as to which of our employees qualify as executive officers was made by the Board in accordance with the rules of the SEC. Biographical information for our executive officers as of the Record Date is set forth below. The following table identifies our current executive officers, their age, and their respective offices and positions as of the Record Date.

| Name                   |     | Age |     | Position                                        |
| Marshall Fordyce, M.D. |     |  51 |     | President, Chief Executive Officer and Director |
| Robert Brenner, M.D.   |     |  57 |     | Chief Medical Officer                           |
| Sean Grant             |     |  40 |     | Chief Financial Officer                         |
| Jason Carter           |     |  49 |     | Chief Legal Officer                             |
| David Johnson          |     |  55 |     | Chief Operating Officer                         |
| William Turner         |     |  59 |     | Chief Development Officer                       |

Marshall Fordyce, M.D. Biographical information regarding Dr. Fordyce is set forth under “Proposal 1: Election of Directors.” Robert Brenner, M.D. has served as our Chief Medical Officer since January 2024. He previously served as co-founder and Chief Executive Officer at Cru Bio, a biopharmaceutical company dedicated to developing innovative therapies to address kidney and related diseases, from August 2022 to December 2023. From February 2020 to February 2022, Dr. Brenner worked in healthcare venture capital for 6 Dimensions Capital and he has participated in the incubation and launch of new kidney disease treatment companies in both the United States and China. Prior to joining 6 Dimensions Capital, Dr. Brenner served as CMO at Orionis Biosciences, LLC, a biotechnology company, from December 2015 to September 2018 and EVP of Research and Development at Codiak Biosciences, Inc., a biotechnology company, from September 2018 to March 2019. Dr. Brenner received his B.A. from Johns Hopkins University and his M.D. from Albert Einstein College of Medicine. He completed his medical residency at Brigham and Women’s Hospital and his nephrology fellowship at Stanford University Medical Center. Sean Grant has served as our Chief Financial Officer since July 202